Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2018
At a glance
- Drugs Sunitinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 21 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Feb 2008 New trial record.